Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder

Study Identifier
MAF/AGN/NS/OAB/006
CT.gov Identifier
NCT02673047
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Bladder Disorder - Overactive Bladder
    • Study Drug
  • botulinum toxin Type A
    • Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    -Patients who receive a Botox® injection for urinary incontinence.
    Exclusion Criteria:
    -Patients not residing in France.

    Protocol Summary

    This study will describe the prescription conditions of botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) or idiopathic overactive bladder (IOAB) as per standard of care in clinical practice in France.

    Study Locations

    Location
    Status
    Location
    Site D'Aix En Provence
    Aix-en-Provence, France, 13616
    Status
    Not applicable
    Location
    CL Toulouse Lautrec
    Albi, France, 81000
    Status
    Not applicable
    Location
    CHU Angers
    Angers, France, 49033
    Status
    Not applicable
    Location
    CH Angouleme
    Angoulême, France, 16959
    Status
    Not applicable
    Location
    CH Avranches Granville
    Avranches, France, 50300
    Status
    Not applicable
    Location
    CH Bagnols Sur Ceze
    Bagnols-sur-Cèze, France, 30200
    Status
    Not applicable
    Showing {first} - {last} of {total} Results